Impact of Etiological Cytogenetic Abnormalities on the Depth of Immunoparesis and Survival in Newly Diagnosed Multiple Myeloma

被引:1
|
作者
Caro, Jessica [1 ]
Cairns, David [2 ]
Menzies, Tom [2 ]
Boyle, Eileen [1 ]
Pawlyn, Charlotte [3 ]
Cook, Gordon [2 ]
Kaiser, Martin [3 ]
Walker, Brian A. [4 ]
Owen, Roger [5 ]
Jackson, Graham H. [6 ]
Morgan, Gareth J. [1 ]
Heaney, Jennifer [7 ]
Drayson, Mark [7 ]
Davies, Faith E. [1 ]
机构
[1] NYU Langone Hlth, Perlmutter Canc Ctr, 168 E 34th St, New York, NY 10016 USA
[2] Univ Leeds, Leeds Inst Clin Trials Res, Leeds, W Yorkshire, England
[3] Inst Canc Res, London, England
[4] Indiana Univ Sch Med, Indianapolis, IN 46202 USA
[5] St James Univ Hosp, Leeds, W Yorkshire, England
[6] Newcastle Univ, Dept Hematol, Newcastle Upon Tyne, Tyne & Wear, England
[7] Univ Birmingham, Inst Immunol & Immunotherapy, Birmingham, W Midlands, England
来源
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷 / 04期
关键词
Immunosuppression; myeloma; infection; plasma cell disorder; monoclonal protein; RISK; THALIDOMIDE; THERAPY; CYCLOPHOSPHAMIDE; DEXAMETHASONE;
D O I
10.1016/j.clml.2021.10.008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Immunoparesis is associated with poor survival in myeloma (MM). We demonstrate that the etiologic cytogenetic abnormality influences the degree and clinical impact of immunoparesis in newly diagnosed patients in a large clinical trial. As the depth of IgM immunoparesis impacts survival for hyperdiploid patients, this may be used to further risk-stratify this cytogenetic subgroup of patients for future clinical decisions. Introduction/Background: Immunoparesis, or low polyclonal immunoglobulin levels, is commonly seen in multiple myeloma (MM), and is associated with poor clinical outcomes. MM can be divided into subgroups with distinct biology and outcomes based on etiologic cytogenetic abnormalities. These include hyperdiploidy and translocations of t(11;14), t(4;14), t(14;16), and t(14;20), with the latter 3 associated with high-risk disease. We hypothesized that the different etiologic cytogenetic abnormalities drive bone marrow microenvironmental changes, resulting in different degrees of immunoparesis, and subgroup-dependent effects on clinical outcomes. Materials and Methods: We performed a retrospective review of 985 newly diagnosed patients enrolled in the Myeloma IX and XI trials. Immunoglobulin levels, survival outcomes, and infection rates were evaluated for each cytogenetic subgroup. Results: A significant proportion of patients with high-risk t(4;14), t(14;16), or t(14;20) had suppressed polyclonal immunoglobulins compared to standard-risk patients with hyperdiploidy or t(11;14). The clinical impact of immunoparesis depended on the cytogenetic subgroup, with the degree of IgM suppression effecting progression-free and overall survival only in the hyperdiploid subgroup. There was no significant difference in infection rates amongst the etiologic subgroups. Conclusion: These findings demonstrate that the etiologic cytogenetic subgroup influences the degree and clinical impact of immunoparesis. This suggests that the underlying cytogenetic abnormality affects remodeling of the bone marrow plasma cell niche, resulting in suppressed normal plasma cell function, and low immunoglobulin levels.
引用
收藏
页码:E279 / E284
页数:6
相关论文
共 50 条
  • [31] IMPACT OF UPFRONT BORTEZOMIB-BASED REGIMENS ON CLINICAL OUTCOMES OF NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS ACCORDING TO CYTOGENETIC ABNORMALITIES BY FISH ANALYSIS
    Cavo, M.
    Palumbo, A.
    Bringhen, S.
    Di Raimondo, F.
    Patriarca, F.
    Rossi, D.
    Levi, A.
    Offidani, M.
    Montefusco, V.
    Narni, F.
    Zambello, R.
    Benevolo, G.
    Grasso, M.
    Falcone, A.
    Musto, P.
    Guglielmelli, T.
    Gherlinzoni, F.
    Gottardi, D.
    Musolino, C.
    Di Renzo, N.
    Masini, L.
    Cangialosi, C.
    Dore, F.
    Ballanti, S.
    Storti, S.
    Angelucci, E.
    Vallone, R.
    Magarotto, V.
    Morabito, F.
    Tosi, P.
    Boccadoro, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 451 - 451
  • [32] The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma
    Evans, Laura A.
    Go, Ronald S.
    Nandakumar, Bharat
    Buadi, Francis K.
    Dispenzieri, Angela
    Dingli, David
    Lacy, Martha Q.
    Hayman, Suzanne R.
    Kapoor, Prashant
    Leung, Nelson
    Fonder, Amie
    Hobbs, Miriam A.
    Hwa, Yi L.
    Muchtar, Eli
    Warsame, Rahma M.
    Kourelis, Taxiarchis
    Russell, Stephen J.
    Lust, John A.
    Siddiqui, Mustaqeem
    Kyle, Robert A.
    Gertz, Morie A.
    Rajkumar, S. Vincent
    Kumar, Shaji K.
    Gonsalves, Wilson I.
    BLOOD, 2019, 134
  • [33] Depth of Pre-Treatment Immunoparesis Is an Important Prognostic Factor for Survival in Relapsed Multiple Myeloma
    Chakraborty, Rajshekar
    Rybicki, Lisa
    Nakashima, Megan
    Dean, Robert M.
    Faiman, Beth M.
    Samaras, Christy J.
    Rosko, Nathaniel
    Valent, Jason
    Anwer, Faiz
    BLOOD, 2019, 134
  • [34] Development of Thrombocytopenia and Survival Outcomes in Newly Diagnosed Multiple Myeloma
    Mellors, Patrick
    Binder, Moritz
    Buadi, Francis K.
    Lacy, Martha Q.
    Gertz, Morie A.
    Dispenzieri, Angela
    Hayman, Suzanne R.
    Kapoor, Prashant
    Gonsalves, Wilson I.
    Hwa, Yi
    Fonder, Amie
    Hobbs, Miriam
    Kourelis, Taxiarchis
    Warsame, Rahma
    Zeldenrust, Steven
    Lust, John A.
    Leung, Nelson
    Go, Ronald S.
    Kyle, Robert A.
    Rajkumar, S. Vincent
    Kumar, Shaji K.
    BLOOD, 2018, 132
  • [35] Time to plateau as a predictor of survival in newly diagnosed multiple myeloma
    Mellors, Patrick W.
    Binder, Moritz
    Buadi, Francis K.
    Lacy, Martha Q.
    Gertz, Morie A.
    Dispenzieri, Angela
    Hayman, Suzanne R.
    Kapoor, Prashant
    Gonsalves, Wilson I.
    Hwa, Yi L.
    Fonder, Amie
    Hobbs, Miriam
    Kourelis, Taxiarchis
    Warsame, Rahma
    Zeldenrust, Steven R.
    Lust, John A.
    Leung, Nelson
    Go, Ronald S.
    Kyle, Robert A.
    Rajkumar, S. Vincent
    Kumar, Shaji K.
    AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (07) : 889 - 894
  • [36] Immunoparesis in newly diagnosed AL amyloidosis as a marker for response and survival.
    Muchtar, Eli
    Dispenzieri, Angela
    Kumar, Shaji
    Buadi, Francis
    Lacy, Martha
    Zeldenrust, Steven R.
    Hayman, Suzanne R.
    Leung, Nelson
    Kourelis, Taxiarchis
    Gonsalves, Wilson I.
    Chakraborty, Rajshekhar
    Russell, Stephen J.
    Dingli, David
    Lin, John Anthony Lustt Yi
    Kapoor, Prashant
    Go, Ronald S.
    Kyle, Robert A.
    Rajkumar, S. Vincent
    Gertz, Marie A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [37] Development of a nomogram prognostic model for early Grade ≥ 3 infection in newly diagnosed multiple myeloma based on immunoparesis
    Zhang, Min
    Cheng, Qianwen
    Zhao, Fei
    Xu, Aoshuang
    Li, Qun
    Hu, Yu
    Sun, Chunyan
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 126
  • [38] CYTOGENETIC ABNORMALITIES IN MULTIPLE-MYELOMA
    BYEFF, P
    HALPER, J
    LOFSTROM, L
    WARBURTON, D
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1981, 22 (MAR): : 43 - 43
  • [39] Multiple copies of MLL as a commonly detected cytogenetic abnormality in newly diagnosed symptomatic multiple myeloma
    Landry, Chrystal Ann
    Londono, Dory
    Devlin, Sean
    Jhanwar, Suresh
    Giralt, Sergio
    Landau, Heather Jolle
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [40] Characterisation and prognostic impact of immunoparesis in relapsed multiple myeloma
    Chakraborty, Rajshekhar
    Rybicki, Lisa
    Nakashima, Megan O.
    Dean, Robert M.
    Faiman, Beth M.
    Samaras, Christy J.
    Rosko, Nathaniel
    Dysert, Hayley
    Valent, Jason
    Anwer, Faiz
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 (06) : 1074 - 1082